2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
11 recruiting
4
Rare Diseases
across 12 areas
0
News (30d)
Quiet
Cerberus Princeton, LLC is a company with 2 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| 22q11.2 deletion syndrome | metyrosine | Des.TrialAppr. |
| DiGeorge syndrome | metyrosine | Des.TrialAppr. |
| manganese poisoning | trientine hydrochloride | Des.TrialAppr. |
| velocardiofacial syndrome | metyrosine | Des.TrialAppr. |
50% of portfolio targets high unmet need diseases
3
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
50% of portfolio targets high unmet need diseases
3
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio